A. David Rodrigues

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Dale J. Kempf, Kennan C. Marsh, Gondi Kumar et al. · Antimicrobial Agents and Chemotherapy · 1997 · 420 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, a Novel Cyclooxygenase-II Inhibitor

Cuyue Tang, Magang Shou, Thomas H. Rushmore et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 159 citations

Medicine, Biochemistry, Pharmacology +16

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Cuyue Tang, Magang Shou, Thomas H. Rushmore et al. · Pharmacogenetics · 2001 · 121 citations

Medicine, Pharmacokinetics, Pharmacology +16

Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs

Daiki Mori, Emi Kimoto, Brian Rago et al. · Clinical Pharmacology & Therapeutics · 2019 · 102 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

Ian M. Bell, Steven N. Gallicchio, Marc Abrams et al. · Journal of Medicinal Chemistry · 2002 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16